ecancer
ecancer is a UK charity which provides accessible, high-quality educational content, free to the global oncology community. Our mission is to raise the standards of care for cancer patients across the world through education.
ASCO 2021
ecancer
2021 ASCO Update on Pancreatic and Hepatobiliary Cancers: Surveying Clinical Data
FEATURING
Caio Rocha Lima
- 303 views
- September 2, 2021
- 1
ecancer
ASCO 2021 Update on IO in NSCLC: Considering Data From the Key Trials
FEATURING
Luis Raez
- 70 views
- September 2, 2021
ecancer
ASCO 2021 Update on Oncogenesis in NSCLC: Overview of Targeting Pathways and Therapies
FEATURING
Edgardo Santos
- 341 views
- September 2, 2021
- 1
ecancer
ASCO 2021 Update on mCRPC: VISION Trial Data on Lutetium-177-PSMA-617
FEATURING
Michael Morris
- 39 views
- September 2, 2021
- 1
ecancer
2021 ASCO Highlights on the Most Recent MDS Trials
FEATURING
Fernando Vargas
- 14 views
- September 2, 2021
ecancer
ASCO 2021 Data on Adjuvant Olaparib for Patients with BRCA1/2-Mutated EBC: OlympiA Trial
FEATURING
Zeina Nahleh
- 36 views
- September 2, 2021
ecancer
ASCO 2021 Update on Targeted Therapy in BC: Surveying Data From Key Trials
FEATURING
Aurelio Castrellon
- 93 views
- September 2, 2021
- 1
ecancer
2021 ASCO Update From ELARA Study on Adult Patients With R/R FL: Efficacy & Safety of Tisagenlecleucel
FEATURING
Stephen Schuster
- 17 views
- August 10, 2021
ecancer
ASCO 2021 Updates From Noteworthy Studies: GYN, H&N, GU, Breast, GI & Skin Cancers
FEATURING
Bishal Gyawali
- 373 views
- August 4, 2021
- 1
ecancer
ASCO 2021 Update on Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Advanced NSCLC
FEATURING
Christina Baik
- 92 views
- August 4, 2021
ecancer
ASCO 2021 Update on RAS Wild-Type mCRC: PANAMA Trial Data on Maintenance 5FU/LV + Panitumumab or 5FU/LV Alone
FEATURING
Dominik Modest
- 82 views
- August 4, 2021
ecancer
Tislelizumab vs. Chemo in 2L for Advanced ESCC: RATIONALE-302 Safety and Efficacy Data
FEATURING
Jaffer Ajani
- 37 views
- August 4, 2021
ecancer
ASCO 2021 Update on Pembrolizumab vs. Chemo in MSI-H/dMMR mCRC: Final OS Results From the KEYNOTE-177 Trial
FEATURING
Thierry André
- 226 views
- August 4, 2021
ecancer
ASCO 2021 RCC Roundup: Surveying Data From the Key Studies
FEATURING
Bradley McGregor
- 34 views
- August 3, 2021
ecancer
2021 ASCO Highlights on mCRPC: Latest Developments in Diagnostics & Combination Therapies
- 73 views
- August 3, 2021
ecancer
ASCO 2021 Highlights on PARPi and Other mCRPC Treatments
FEATURING
Neal Shore,
Oliver Sartor
- 33 views
- August 3, 2021
ecancer
ASCO 2021 Update on Newly Diagnosed mHSPC: ADT + TAK-700 With ADT + Bicalutamide
FEATURING
Neeraj Agarwal
- 14 views
- August 3, 2021
ecancer
ASCO 2021 Update on Precision and Molecular Reporting for mCRPC: Radioligand Therapy & Bone-Protecting Agents
FEATURING
Eleni Efstathiou
- 304 views
- August 3, 2021
- 3
ecancer
ASCO 2021 Update on Adjuvant Olaparib in High-Risk HER2- EBC With BRCA 1/2 Mutations: Considering OlympiA Trial Data
FEATURING
Andrew Tutt
- 13 views
- August 3, 2021
ecancer
Clinically Sufficient Vitamin D Levels at BC Diagnosis & Survival Outcomes: Methodology and Key Findings of the VITAL Trial
FEATURING
Song Yao
- 11 views
- August 3, 2021
ecancer
ASCO 2021 Breast Cancer Roundup on Early & Advanced Setting of BC: Surveying Key Takeaways
FEATURING
Matteo Lambertini
- 16 views
- August 3, 2021
ecancer
2021 ASCO Review on KEYNOTE-564: Pembro vs. Placebo as Post-Nephrectomy Adjuvant Therapy for Patients with RCC
FEATURING
Toni Choueiri
- 32 views
- July 20, 2021
ecancer
2021 ASCO Highlights on Amivantamab + Lazertinib for Osimertinib-Relapsed, Chemo-Naive EGFRm NSCLC
FEATURING
Joshua Sabari,
Anna Minchom
- 26 views
- July 20, 2021
